Download (4Mb) - Etheses - Saurashtra University

Part-1Review on Antiulcer LiteratureTable 3. Pharmacological properties of the different proton pump inhibitorsHalf Peak Duration BioavailGeneric name-life effect of effect abilitypKa(h) (h) (h)(%)MetabolismOmeprazole 63 0.7 2 24-72 ~4 30-40 ExtensivelyhepaticPantoprazole 64 1 2.5 24-72 ~4 77 ExtensivelyhepaticLansoprazole 65 2 1.7 >24 ~4 80 ExtensivelyhepaticRabeprazole 66 1 2-5 24 ~5 52 ExtensivelyhepaticEsomeprazole 67 1.3 1.5 24-27 ~4 64 ExtensivelyhepaticU=urine; pKa=dissociation constant; F=faecesExcretion(%)U=77F=23U=71F=18U=35F=65U=90F=10U=80F=201.6. Reversible Proton Pump Inhibitor’s1.6.1. IntroductionProlonged suppression of gastric acid secretion produced by both H 2 receptor antagonistsand PPIs produce extended periods of hypergastrinemia, which has been associated withthe formation of precancerous changes in human gastric mucosa and gastric carcinoids inlong term animal studies. However, research efforts are currently targeted at obtainingreversible proton pump inhibitors often referred as Acid Pump Antagonists (APAs).Several research groups have progressed APAs into development though currently noneis marketed. 2The imidazopyridine based compound SCH28080 23 was the prototype of this class. 68Antisecretory effect of this compound is mediated through gastric proton pump and thishas been further demonstrated by its ability to antagonize the binding of omeprazole. 6924